A replacement for chemotherapy?
Metastasis is a process where cancer cells of primary tumors gain properties enabling them to escape from the primary tumor and move to a secondary location in the body where they develop additional tumors. This event in advanced tumor progression subsequently results in >90% of all cancer patient deaths and there are currently no effective therapies to either prevent or treat metastatic cancer. In my lab at the Washington University School of Medicine in Saint Louis, we now have developed new small molecules which potently inhibit three key proteolytic enzymes, HGFA, matriptase and hepsin, which are essential for tumor progression and metastasis.
Similar to a blocked fuel pump in a vehicle which stops a car from moving and its engine from running, these inhibitors stop cancer cell signaling by cutting off the fuel (the growth factors HGF and MSP) supply to its engines, the c-MET and RON kinase receptors. The inhibitors block the processing of both HGF and MSP by the enzymes (oil refineries) and, without the fully refined growth factors, the kinase receptors cannot turn or stay on. Depending on the cancer type, an inhibitor of one or more of these enzymes will be necessary to block signaling and metastasis. We have rationally designed a complete set of seven compound subsets encompassing all such possible combinations in hand which inhibit:
- HGFA, matriptase and hepsin
- HGFA and matriptase
- HGFA and hepsin
- matriptase and hepsin
- HGFA only
- matriptase only
- hepsin only
These exciting compounds are a powerful toolkit of new drugs for the treatment and prevention of metastatic cancer. The inhibitors, now in preclinical testing, have potential to 1) treat tumors that are chemoresistant to targeted kinase inhibitors and 2) to replace standard adjunct chemotherapy (post-surgery) altogether with safer and more effective therapeutics without the debilitating side-effects normally encountered in current cancer therapy.
James W. Janetka, Ph.D.
Associate Professor of Biochemistry & Molecular Biophysics
Adjunct Professor of Chemistry, Washington University
Saint Louis, USA
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW.
Bioorg Med Chem. 2015 May 15
|Making drug discovery more efficient: predicting… Drug research and development is a complex and expensive process that begins with initial screening steps of candidate chemical compounds. Compounds that appear to have the desired potency against a…|
|Using nanotechnology to outsmart pancreatic cancer Cancer is a versatile disease and makes use of complex cellular signaling networks to defend itself against a host of treatments. Pancreatic cancer in particular has proven challenging with tenacious…|
|Cyagen Biosciences – Helping you choose the right… While many animal models are available “ off the shelf ” through various repositories and collaborations, generation of novel animal models has allowed for more effective studies, not limited by…|
|VIRTUOSO: Virtual clinical trials concept to help… The use of anti-cancer drugs (chemotherapy) is one of the standard-of-care therapeutic treatments routinely applied in clinics. However, a significant portion of patients who show a good initial response to…|
|Melanoma is controlling metastasis of melanoma… The title is provocative, because most will most ask: but who other than mm can control the metastasis of melanoma? But let's get on the path of facts and procedures…|
|In silico prediction of ebolavirus RNA polymerase inhibition A virus at work: Let us assume that you are a virus that just infected a cell (the HOST CELL) of an individual (the PATIENT). What is your vicious objective?…|